126 related articles for article (PubMed ID: 27780361)
1. VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.
Camerin GR; Brito AB; Vassallo J; Derchain SF; Lima CS
Future Oncol; 2017 Feb; 13(5):409-414. PubMed ID: 27780361
[TBL] [Abstract][Full Text] [Related]
2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
4. Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.
Carron J; Brito AB; Torelli AC; Oliveira C; Derchain SF; Lima CS; Lourenço GJ
Med Oncol; 2016 Oct; 33(10):112. PubMed ID: 27586145
[TBL] [Abstract][Full Text] [Related]
5. Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
González-Palomares B; Coronado Martín PJ; Maestro de Las Casas ML; Veganzones de Castro S; Rafael Fernández S; Vidaurreta Lázaro M; De la Orden García V; Vidart Aragon JA
Int J Gynecol Cancer; 2017 Jul; 27(6):1088-1095. PubMed ID: 28574932
[TBL] [Abstract][Full Text] [Related]
6. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
8. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
9. nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease.
Li Y; Kang S; Qin JJ; Wang N; Zhou RM; Sun HY
Gynecol Oncol; 2012 Sep; 126(3):455-9. PubMed ID: 22683585
[TBL] [Abstract][Full Text] [Related]
10. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Krivak TC; Darcy KM; Tian C; Armstrong D; Baysal BE; Gallion H; Ambrosone CB; DeLoia JA;
J Clin Oncol; 2008 Jul; 26(21):3598-606. PubMed ID: 18640939
[TBL] [Abstract][Full Text] [Related]
11. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.
Shimogai R; Kigawa J; Itamochi H; Iba T; Kanamori Y; Oishi T; Shimada M; Sato S; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2008; 18(3):499-505. PubMed ID: 18476949
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers.
Bhaskari J; Premalata CS; Shilpa V; Rahul B; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2016 Jan; 37(1):1017-23. PubMed ID: 26264619
[TBL] [Abstract][Full Text] [Related]
14. Prediction value of intercellular adhesion molecule-1 gene polymorphisms for epithelial ovarian cancer risk, clinical features, and prognosis.
Cai G; Ma X; Zou W; Huang Y; Zhang J; Wang D; Chen B
Gene; 2014 Aug; 546(1):117-23. PubMed ID: 23933413
[TBL] [Abstract][Full Text] [Related]
15. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Apr; 117(1):109-16. PubMed ID: 20056267
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer.
Wang M; He Y; Shi L; Shi C
Eur J Gynaecol Oncol; 2011; 32(2):171-7. PubMed ID: 21614907
[TBL] [Abstract][Full Text] [Related]
17. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
[TBL] [Abstract][Full Text] [Related]
20. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
Li Y; Hu P; Cao Y; Wang GY; Wang N; Zhou RM
Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
